ClinicalTrials.gg
Active, not recruitingNCT06973304Updated Sep 8, 2026

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Takeda. Active, not recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
12th of 20
13 · median 20
Started
2025
the only one that year
Phase 3
16 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
3 of 20
Takeda

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 12th largest by enrollment, is the only one that started in 2025, is one of 16 in phase 3, and was the 19th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide.

Participants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment.

Participants will be in the study for about 65 weeks.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females 18 years of age or older at the time of signing the .
  2. Intestinal failure due to SBS as a consequence of major intestinal resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's disease).
  3. Has undergone intestinal resection resulting in at least 12 continuous months of PS dependency prior to signing the informed consent.
  4. Requires PS at least 3 times per week or at least 4 liters per week during the 2 weeks prior to baseline to meet caloric, fluid, or electrolyte needs due to ongoing malabsorption.
  5. Has a stable PS requirement for at least 4 consecutive weeks immediately prior to the start of teduglutide treatment. Stability is defined as follows:

    1. Actual PS usage is similar to prescribed PS.
    2. Baseline (Visit 2) 48-hour intake (I)/output (O) volumes should fall within +-25% of the respective 48-hour I/O volumes at the last optimization visit.
    3. The 48-hour urine output volume must not be less than 2 liters and should not exceed 4 liters at the last optimization visit, the stabilization visit, and the baseline visit.
  6. Participants with a history of Crohn's disease must be in endoscopic remission for at least 12 weeks prior to the baseline visit.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating female.
  2. Participation in a clinical study using an experimental drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or concurrent participation in any other clinical study.
  3. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these hormones within the past 6 months prior to the baseline visit.
  4. Use of octreotide, GLP-1 analogs, or dipeptidyl peptidase-4 inhibitors within 30 days prior to the baseline visit.
  5. Previous use of teduglutide.
  6. Active inflammatory bowel disease (IBD) or any participant with IBD requiring therapy (example, azathioprine,anti-tumor necrosis factor [anti-TNF]) drugs) that had been introduced or changed within the past 6 months prior to the baseline visit.
  7. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, familial adenomatous polyposis.
  8. Chronic intestinal pseudo-obstruction or severe dysmotility.
  9. intestinal stenosis or obstruction, or evidence of such on upper gastrointestinal (UGI)/small bowel follow-through (SBFT), within the past 6 months prior to the baseline visit.
  10. Major gastrointestinal (GI) surgical intervention, including significant intestinal resection, within the past 3 months (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections less than or equal to [\<=] 10 centimeter [cm], or endoscopic procedure is allowed) prior to the baseline visit.
  11. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or congenital heart disease).
  12. Moderate or severe renal impairment, defined as less than 50 milliliters per minute (mL/min).
  13. Currently diagnosed with cancer or a history of any cancer except surgically cured skin cancer within the past 5 years.
  14. Severe hepatobiliary disease including any of the following:

    1. Total level at least 2 times the (ULN), except for increased indirect (unconjugated) bilirubin in a patient with Gilbert's syndrome.
    2. at least 5*ULN.
    3. ALT at least 5*ULN
  15. Active clinically significant pancreatic disease, including clinical signs of pancreatitis associated with elevations in serum amylase or lipase at least 2*ULN.
  16. More than 4 SBS-related or PS-related hospital admissions (example, central line-associated bloodstream infection, bowel obstruction, severe fluid/electrolyte disturbances) within the past 12 months prior to the baseline visit.
  17. Unscheduled hospitalization within 30 days prior to screening.
  18. Non-herpetic viral diseases:

    1. Presence of virus (HCV) antibody and a positive confirmatory test result for HCV RNA (ribonucleic acid) (nucleic acid test or polymerase chain reaction).
    2. Presence of ( Surface Antigen Positive [HBsAg+]). For participants who are negative for HBsAg but are positive for either surface antibodies and/or core antibodies, hepatitis B virus (HBV) deoxyribonucleic acid (DNA) polymerase chain reaction will be performed; if any test result meets or exceeds detection sensitivity, the subject will be excluded.
    3. Positive results for (HIV) by serology, regardless of viral load.
  19. Any condition, disease, illness, or circumstance that in the investigator's opinion puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results. Example of potential disease state/illnesses that may be excluded are listed in the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Teduglutide 0.05 milligram per kilogram (mg/kg)

    Participants will receive teduglutide 0.05 mg/kg subcutaneous (SC) injection, once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.

    Drug: Teduglutide

Interventions

  • Teduglutide 0.05 mg/kg SC injection.

    Also known as: TAK-633, A16AX08, Revestive, Gattex

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20 and Maintained Through Week 24

    Time frame: Up to Week 24

Secondary outcomes

  1. Absolute Change From Baseline in Weekly PS Volume up to Week 24

    Time frame: Baseline up to Week 24

  2. Percent Change From Baseline in Weekly PS Volume up to Week 24

    Time frame: Baseline up to Week 24

  3. Absolute Change From Baseline in Days Per Week of PS up to Week 24

    Time frame: Baseline up to Week 24

  4. Percent Change From Baseline in Days Per Week of PS up to Week 24

    Time frame: Baseline up to Week 24

  5. Number of Participants Who Achieved At Least 20% Reduction From Baseline in Weekly PS Volume at each visit

    Time frame: Up to Week 24

  6. Number of Participants With At Least a 20% Reduction From Baseline in Weekly PS at Week 20 and Maintained Through Week 24

    Time frame: Baseline, Week 20 and Week 24

  7. Number of Participants With At Least a 2-liter Reduction From Baseline in Weekly PS at Week 20 and Maintained Through Week 24

    Time frame: Baseline, Week 20 and Week 24

  8. Number of Participants who are able to Completely Wean off of PS support at Week 24

    Time frame: At Week 24

  9. Time From First Dose to Time of Completely Weaning off of PS Support

    Time frame: Up to Week 24

  10. AUC0-inf: Area Under the Plasma Concentration-time Curve From Time 0 to Time of Infinity for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  11. AUC0-last: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  12. Cmax: Maximum Observed Plasma Concentration for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  13. Tmax: Time to Reach the Cmax for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  14. T1/2: Terminal Phase Half-life for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  15. CL/F: Apparent Clearance for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  16. V/F: Apparent Volume of Distribution During the Terminal Elimination Phase for Teduglutide

    Time frame: Predose, 1, 2, 4, 6, 8, and 10 hours post-dose

  17. Plasma Concentrations of Teduglutide

    Time frame: At Week 4 and Week 24

  18. Number of Participants With Positive Antidrug Antibodies (Neutralizing and Non-neutralizing)

    Time frame: Baseline, Week 4, and Week 24

  19. Number of Participants Who Experienced At Least One Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)

    Time frame: From first dose of study drug up to follow-up (Week 48)

  20. Change From Baseline in 48-hour Urine Output

    Time frame: Baseline up to 48 hours

  21. Change From Baseline in Body Weight

    Time frame: Baseline up to Week 48

  22. Change From Baseline in Body Mass Index

    Time frame: Baseline up to Week 48

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 15, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Feb 10, 2027
CompletionEst.
Jul 28, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973304
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jun 26, 2025
Primary completion
Feb 10, 2027 (estimated)
Completion
Jul 28, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion